公开(公告)号：US11419844B2

公开(公告)日：2022-08-23

申请号：US16688319

申请日：2019-11-19

申请人： Provectus Pharmatech, Inc. ,  UTI Limited Partnership

发明人： Eric A. Wachter ,  Dominic Rodrigues ,  Satbir Thakur ,  Lucy Swift ,  Chunfen Zhang ,  Mohit Jain ,  Aru Narendran

IPC分类号： A61K31/352 ,  A61P35/00 ,  C07K16/28

摘要： A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.

公开(公告)号：US20220054449A1

公开(公告)日：2022-02-24

申请号：US17466600

申请日：2021-09-03

申请人： The Rockefeller University ,  Provectus Pharmatech, Inc.

发明人： James G. Krueger ,  Sandra Garcet ,  Jamie Singer ,  Eric A. Wachter

IPC分类号： A61K31/352 ,  A61K9/00 ,  A61K45/06 ,  A61P17/04 ,  A61P17/06 ,  A61K31/52 ,  A61K31/4035 ,  A61K9/06 ,  A61K31/69 ,  A61K31/519 ,  A61K38/13

摘要： A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-α, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors. Treatment of other epithelial tissue, such as the lining of the gut, is also disclosed.

公开(公告)号：US20220008534A1

公开(公告)日：2022-01-13

申请号：US17382943

申请日：2021-07-22

申请人： Provectus Pharmatech, Inc.

发明人： Eric A. Wachter

IPC分类号： A61K39/395 ,  A61K47/60 ,  A61K31/365 ,  A61K38/20 ,  A61K38/21 ,  C07K16/30 ,  A61K38/19 ,  A61K31/352 ,  A61K39/00 ,  A61K39/245 ,  A61K47/02 ,  C12N7/00 ,  A61K45/06

摘要： A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.

公开(公告)号：US11058664B2

公开(公告)日：2021-07-13

申请号：US16412872

申请日：2019-05-15

申请人： Provectus Pharmatech, Inc. ,  UTI Limited Partnership

发明人： Jamie Singer ,  Eric A. Wachter ,  Satbir Thakur ,  Lucy Swift ,  Chunfen Zhang ,  Mohit Jain ,  Aru Narendran

IPC分类号： A61K31/343 ,  C07K16/28 ,  A61K45/06

摘要： A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.

公开(公告)号：US20210236418A1

公开(公告)日：2021-08-05

申请号：US17232393

申请日：2021-04-16

申请人： Provectus Pharmatech, Inc, ,  UTI Limited Partnership

发明人： Aru Narendran ,  Dominic Rodrigues ,  Bruce Horowitz ,  Edward V. Pershing ,  Eric A. Wachter

IPC分类号： A61K9/00 ,  A61K45/06 ,  A61P35/02 ,  A61K31/352

摘要： A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.

公开(公告)号：US20190030074A1

公开(公告)日：2019-01-31

申请号：US16149468

申请日：2018-10-02

申请人： Provectus Pharmatech, Inc. ,  H. Lee Moffitt Cancer Center and Research Institute, Inc.

发明人： Jamie SINGER ,  Eric A. WACHTER ,  Amod SARNAIK ,  Shari PHILON-THOMAS ,  Hao LIU

IPC分类号： A61K35/17 ,  A61K38/17 ,  A61K39/395 ,  A61K38/21 ,  A61K39/00 ,  A61K31/352 ,  C12P21/00 ,  C12P21/02 ,  A61K35/15 ,  C07K16/28

摘要： A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.

公开(公告)号：US20180055926A1

公开(公告)日：2018-03-01

申请号：US15804357

申请日：2017-11-06

申请人： Provectus Pharmatech, Inc. ,  Pfizer, Inc.

发明人： Craig J. EAGLE ,  H. Craig DEES ,  Eric A. WACHTER ,  Jamie SINGER

IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K31/352 ,  A61K31/365 ,  C12N7/00 ,  C07K16/30 ,  A61K47/02 ,  A61K45/06 ,  A61K39/245 ,  A61K38/21 ,  A61K38/20 ,  A61K38/19

CPC分类号： A61K39/3955 ,  A61K31/352 ,  A61K31/365 ,  A61K38/193 ,  A61K38/20 ,  A61K38/2006 ,  A61K38/2013 ,  A61K38/204 ,  A61K38/21 ,  A61K38/212 ,  A61K38/217 ,  A61K39/0005 ,  A61K39/0011 ,  A61K39/245 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/02 ,  A61K47/60 ,  A61K2039/505 ,  C07K16/30 ,  C12N7/00 ,  C12N2710/16021 ,  C12N2710/16034

摘要： A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.

公开(公告)号：US09808524B2

公开(公告)日：2017-11-07

申请号：US14748634

申请日：2015-06-24

申请人： Provectus Pharmaceuticals, Inc. ,  Pfizer, Inc.

发明人： Craig J. Eagle ,  H. Craig Dees ,  Eric A. Wachter ,  Jamie Singer

IPC分类号： A61K39/395 ,  A61K31/352 ,  A61K38/21 ,  C07K16/30 ,  A61K31/365 ,  A61K38/19 ,  A61K38/20 ,  A61K39/00 ,  A61K39/245 ,  A61K45/06 ,  A61K47/02 ,  A61K47/60 ,  C12N7/00

CPC分类号： A61K39/3955 ,  A61K31/352 ,  A61K31/365 ,  A61K38/193 ,  A61K38/20 ,  A61K38/2006 ,  A61K38/2013 ,  A61K38/204 ,  A61K38/21 ,  A61K38/212 ,  A61K38/217 ,  A61K39/0005 ,  A61K39/0011 ,  A61K39/245 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/02 ,  A61K47/60 ,  A61K2039/505 ,  C07K16/30 ,  C12N7/00 ,  C12N2710/16021 ,  C12N2710/16034

摘要： A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.

公开(公告)号：US20100076246A1

公开(公告)日：2010-03-25

申请号：US12543653

申请日：2009-08-19

申请人： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

发明人： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

IPC分类号： A61N5/10 ,  A61K31/352 ,  A61P35/04

CPC分类号： A61K31/352 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61K9/0019 ,  A61K41/0038 ,  A61N5/0601 ,  A61N5/062 ,  A61N5/10 ,  A61N2005/1098 ,  C07D311/82

摘要： New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

摘要翻译： 描述了新的体内放射碘化物药物和用于治疗人或动物组织的这种高能光疗药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤化呫吨衍生物。 卤化呫吨构成了一种有效的放射增敏剂，其在用电离辐射照射治疗部位时变得光活化。 在本发明的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官的各种病症， 循环系统和相关器官，头颈部，内分泌和淋巴系统及相关器官，各种其他组织，例如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个实施方案中，这些药物是以包括液体，半固体，固体或气溶胶输送载体在内的各种制剂生产的。

公开(公告)号：US07648695B2

公开(公告)日：2010-01-19

申请号：US09900355

申请日：2001-07-06

申请人： H. Craig Dees ,  Timothy C. Scott

发明人： H. Craig Dees ,  Timothy C. Scott

IPC分类号： A61K51/00 ,  A61M36/14 ,  G01N33/00

CPC分类号： A61K41/0057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/352 ,  A61K41/0071 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/193333

摘要： New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations useful for intracorporeal or topical administration, including in liquid, semisolid, solid or aerosol delivery vehicles.

摘要翻译： 描述了新的化学治疗药物和用于治疗人或动物组织中的这种化学治疗药物的某些医疗用途和方法，其中这种药物的主要活性成分是卤化呫吨或卤代呫吨衍生物。 优选地，卤代呫吨是玫瑰红或玫瑰红的功能衍生物。 卤代呫吨构成一系列有用的化学治疗剂，其在某些组织中提供选择性的，持续的积累。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官，循环系统 内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个优选的实施方案中，这些药物可用于体内或局部给药的各种制剂，包括在液体，半固体，固体或气溶胶输送载体中。